Cart
sales@molnova.com
Tiragolumab
CAS No. 1918185-84-8
Tiragolumab( —— )
Catalog No. M34760 CAS No. 1918185-84-8
Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 424 | In Stock |
|
| 10MG | 682 | In Stock |
|
| 25MG | 1036 | In Stock |
|
| 50MG | 1367 | In Stock |
|
| 100MG | 1841 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTiragolumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).
-
DescriptionTiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1918185-84-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mohammed Sqalli Houssaini, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239.?
molnova catalog
related products
-
PODOPHYLLIN
PODOPHYLLIN
-
IR820-PTX
IR820-PTX is a nanoparticle composed of IR-820 and paclitaxel that is highly permeable and tumor-targeting.IR820-PTX can be used for near-infrared fluorescence imaging and tumor diagnostics.
-
Suc-APA-pNA
Suc-APA-pNA
